

ANTEOBIND ORDER RECEIVED AND LIFE SCIENCES UPDATE

BRISBANE, AUSTRALIA, 12 June 2025: AnteoTech Ltd (ASX:ADO) (AnteoTech or the Company) is pleased to provide this update in relation to the Life Sciences Business Unit

KEY POINTS

- Sales order from the Serum Institute of India under five-year Purchase Agreement of A\$213,000 received¹.
- AnteoTech's Life Sciences (LS) business on track to achieve ~A\$0.93 million sales for FY2025, an increase of approximately 130% over FY2024.
- While the Vidcare project has been delayed due to Indian regulatory requirements, our collaborative relationship continues to grow.
- Prototype assay development program on behalf of KOMA in South Korea has been successfully completed with a further follow-up program of work awaiting approval.

SALES UPDATE

1. Serum Institute of India (SII)

AnteoTech is pleased to advise that it has received a further purchase order from the SII for its **AnteoBind™** product, for US\$138,750 (~A\$213,000)². This order, in conjunction with others, takes SII beyond the minimum annual order quantity (US\$370,000) for FY2025, under the terms of the five-year purchase agreement announced last year¹ and reflects the increasing use case for **AnteoBind™** at SII. This is a positive step forward in the growing relationship between SII and AnteoTech.

AnteoTech looks forward to welcoming and hosting SII executives at our Brisbane headquarters in the near future, as we continue to strengthen our business relationship. The dates of this visit are still in discussion to accommodate busy schedules.

2. Vidcare Innovations (Vidcare)

While Vidcare is awaiting approvals for clinical trials for their first test, the AnteoTech LS team has been working closely with them to enable platform adoption (for both current Thyroid Stimulating Hormone (TSH) and future tests) as well as particle qualification with **AnteoBind NXT™**. Unexpected logistics delays have impacted the timing of this work. The relationship with Vidcare continues to grow.

3. KOMA Biotech Inc (KOMA)

The AnteoTech LS team has successfully completed development of a prototype lateral flow assay device on behalf of KOMA Biotech for a South Korean local customer. Following the supply of the report, AnteoTech is awaiting final payment (of around A\$17,500) to close out this service contract and has a proposal with KOMA in relation to a further work package.

¹ See ASX announcement: "US\$1.8m AnteoBind Purchase Agreement over 5 years", 30 July 2024

² Source: <https://www.xe.com>. (1 AUD = 0.65135 USD)

SUMMARY

AnteoTech's LS Business Unit is on track to achieve ~A\$0.93 million sales for FY2025, a year-on-year increase in sales revenue of approximately 130%.

AnteoTech Interim Managing Director & Chief Executive Officer Merrill Gray, commented:

*"The Life Sciences team is doing a great job at deepening the relationships with our existing customers, demonstrating the value of our products in a range of end uses and attracting new customers. We are developing a range of programs to significantly expand the pipeline of opportunities and our customer base for **AnteoBind™** and **AnteoBind NXT™** over FY2026, aligned with this week's Strategic Review Outcomes announcement."*

This announcement has been authorised for release by the Board of AnteoTech Ltd.

- ENDS -

Media and investor enquiries: on +61 7 3219 0085 or investors@anteotech.com

Company and Partnering enquiries: Merrill Gray, CEO/MD, on + 61 7 3219 0085.

For further information, please check our website www.anteotech.com

About KOMA

KOMA Biotech Inc. is headquartered in Seoul, South Korea. While KOMA is a distributor of reagents and tools for life science research they also develop and supply their own internally products under the LABIS KOMA brand to customers globally. KOMA's products support applications in all major life science research areas, including molecular biology, immunology, neuroscience, cell biology, proteomics and genomics research.

About AnteoTech - (ASX:ADO)

AnteoTech is a supplier of advanced material solutions to the battery materials and life sciences markets. We leverage our market leading binding chemical platform technology to develop and commercialise material solutions for our global customer base. From our patented cross linker and binder product AnteoX™ to our next-generation high silicon anode formulations, Ultranode™, our Advanced Battery Technology division is applying its unique engineering expertise to address the growing demand for high performance, low cost, sustainable materials within the global battery market. Our Life Sciences division supplies advanced activation materials through our AnteoBind™ suite of products to leading developers of diagnostic tests which enable faster, more reliable and accurate test results wherever needed.

AnteoTech - Social Media Policy

AnteoTech is committed to communicating with the investment community through all available channels. Whilst ASX remains the prime channel for market sensitive news, investors and other interested parties are encouraged to follow AnteoTech on LinkedIn. Subscribe to AnteoTech Latest News emails - visit our website at www.anteotech.com and subscribe to receive our email alert service.

Forward Looking Statements

This Announcement may contain forward-looking statements, including estimates, projections and other forward-looking information (**Estimates** and **Projections**). Forward-looking statements can generally be identified by the use of forward-looking words such as "expect", "anticipate", "likely", "intend", "should", "could", "may", "predict", "plan", "propose", "will", "believe", "forecast", "estimate", "target", "outlook", "guidance" and other similar expressions within the meaning of securities laws of applicable jurisdictions and include, but are not limited to, indications of, or guidance or outlook on, future earnings or financial position or performance of AnteoTech. The

Estimates and Projections are based on information available to AnteoTech as at the date of the Announcement, are based upon management's current expectations, estimates, projections, assumptions and beliefs regarding future events in respect to AnteoTech' business and the industry in which it operates which may in time prove to be false, inaccurate or incorrect. The Estimates and Projections are provided as a general guide and should not be relied upon as an indication or guarantee of future performance. The bases for these statements are subject to risk and uncertainties that might be out of control of AnteoTech and may cause actual results to differ from the Announcement. No representation, warranty, or guarantee, whether express or implied, is made or given by AnteoTech in relation to any Estimates and Projections, the accuracy, reliability, or reasonableness of the assumptions on which the Estimates and Projections are based, or the process of formulating any Estimates and Projections, including that any Estimates and Projections contained in this Announcement will be achieved. AnteoTech takes no responsibility to make changes to these statements to reflect change of events or circumstances after the release.